GlassScriptPhysician profile
Joan Stoykovich
NPI 1750467346
$4,469.32
in general payments reported to CMS, 2019-2025
40 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $519 · 2024: $1,941 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Education: $199 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,166.16 |
| Education | $198.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $552.24 | 2023-2025 | Imfinzi, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $467.50 | 2024-2025 | Erleada, Balversa, Akeega |
| Daiichi Sankyo INC. | $454.58 | 2023-2025 | Enhertu |
| Amgen INC. | $248.18 | 2024-2025 | Evenity, Prolia, Prolia |
| Incyte Corporation | $228.28 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $215.37 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $206.33 | 2023-2025 | Keytruda |
| Karyopharm Therapeutics INC. | $194.52 | 2023-2025 | Xpovio |
| Emd Serono, INC. | $149.76 | 2023-2025 | Bavencio |
| Puma Biotechnology, INC. | $149.69 | 2023-2024 | |
| Glaxosmithkline, LLC. | $145.84 | 2024-2025 | Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $138.60 | 2023-2024 | Ninlaro, Iclusig, Fruzaqla |
| Acrotech Biopharma INC. | $128.83 | 2023-2024 | Beleodaq |
| Coherus Oncology, INC. | $107.46 | 2024-2025 | Loqtorzi |
| Immunocore Limited | $97.31 | 2023 | Kimmtrak |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Stoykovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.